Boston, MA 的 胰臟癌 臨床試驗
43 項針對 胰臟癌 的研究正在 Boston（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
招募中1/2 期
- Research Site, Boston
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
招募中1 期
- Dana-Farber Cancer Institute, Boston
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
招募中1 期
- Massachusetts General Hospital, Boston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
招募中2 期
- Dana-Farber Cancer Institute - Oncology Department, Boston
Distance-Based Exercise to Preserve Function and Prevent Disability
招募中
- Dana-Farber Cancer Institute, Boston
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
招募中1 期
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of PHN-012 in Patients With Advanced Solid Tumors
招募中1 期
- PHN-012-001 Site, Boston
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
招募中3 期
- Dana Farber Cancer Institute, Boston
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
招募中3 期
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute (DFCI), Boston
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
招募中3 期
- Investigative Site US022, Boston
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
招募中1/2 期
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
招募中1/2 期
- Dana Farber Cancer Institute, Boston
Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts
招募中觀察性研究
- Dana-Farber Cancer Institute, Boston
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
招募中1/2 期
- Massachusetts General Hospital - Main Campus, Boston
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
招募中1 期
- Dana-Farber Cancer Institute, Boston
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
招募中2 期
- Local Institution - 0124, Boston
Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study
招募中觀察性研究
- Boston Children's Hospital, Boston
Resilience and Equity in Aging, Cancer, and Health (REACH)
招募中
- Dana-Farber Cancer Institute, Boston
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
招募中2 期
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Pancreatic Cancer Early Detection Consortium
招募中觀察性研究歡迎健康志工
- Massachusetts General Hospital, Boston
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
招募中1 期
- Dana-Farber/Massachusetts General Hospital, Inc, Boston
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
招募中1 期
- Mass General Brigham Cancer Institute at Massachusetts General Hospital, Boston
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
招募中1 期
- Research Site, Boston
- Research Site, Boston
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
招募中1 期
- Dana Farber Cancer Institute, Boston
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
招募中1 期
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
招募中早期第 1 期歡迎健康志工
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Video Education With Result Dependent dIsclosure
招募中
- Dana Farber Cancer Institute, Boston
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
招募中1/2 期
- Dana Farber Cancer Institute, Boston
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
招募中1/2 期
- Massachusetts General Hospital, Boston
A Study of MGC028 in Participants With Advanced Solid Tumors
招募中1 期
- Mass General Brigham, Boston
- Dana Farber/Harvard Cancer Center, Boston
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
招募中1/2 期
- Massachusetts General Hospital, Boston
Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer
招募中2 期
- Beth Israel Deaconess Medical Center - Division of Hematology/Oncology, Boston
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
招募中1/2 期
- Dana-Farber Cancer Institute, Boston
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
招募中2 期
- Massachusetts General Hospital, Boston
Resistance Exercise Combined With Protein Supplementation in People With Pancreatic Cancer: The RE-BUILD Trial
招募中
- Dana Farber Cancer Institute, Boston
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
招募中2 期
- Ohio State University-Telemedicine, Boston
The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer
招募中3 期
- Beth Israel Deaconess Medical Center, Boston
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
招募中1/2 期
- Massachusetts General Hospital, Boston
Stereotactic Magnetic Resonance Guided Radiation Therapy
招募中
- Brigham & Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
The Cancer of the Pancreas Screening-5 CAPS5)Study
招募中3 期
- Dana Farber Cancer Center, Harvard University, Boston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
招募中1/2 期
- Dana Farber Cancer Institute, Boston
Confocal Laser Endomicroscopy as an Imaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions
招募中觀察性研究
- Beth Israel Deaconess Medical Center, Boston
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
招募中1 期
- Dana Farber/Partners Cancer Care Inc, Boston
其他城市的 胰臟癌 試驗
- Houston, TX61 項研究
- New York City, NY60 項研究
- Nashville, TN39 項研究
- Los Angeles, CA35 項研究
- St. Louis, MO33 項研究
- Arlington, VA33 項研究
- Baltimore, MD31 項研究
- San Antonio, TX31 項研究
- Philadelphia, PA26 項研究
- Tampa, FL26 項研究
- Durham, NC24 項研究
- San Diego, CA24 項研究
Boston 的其他研究
- 乳癌112 項研究
- 非小細胞肺癌90 項研究
- 癌症（所有類型）85 項研究
- 轉移性癌症63 項研究
- 大腸直腸癌63 項研究
- 肺癌62 項研究
- 卵巢癌61 項研究
- 前列腺癌59 項研究
- 憂鬱症52 項研究
- 子宮內膜癌50 項研究
- 心臟衰竭44 項研究
- 急性髓系白血病44 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。